

# Maria Guarino

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2614857/maria-guarino-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

1,245

citations

21

h-index

32

g-index

81

ext. papers

1,701

ext. citations

5.2

avg, IF

4.16

L-index

#	Paper	IF	Citations
66	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 822507	5.3	0
65	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 824879	5.6	
64	COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study.. <i>Scientific Reports</i> , <b>2022</b> , 12, 4831	4.9	1
63	Vitamin D deficiency and hidradenitis suppurativa: the impact on clinical severity and therapeutic responsivity. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 32, 843-844	2.8	3
62	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13542	4.6	5
61	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , <b>2021</b> , 3, 100260.3	10.3	11
60	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , <b>2021</b> , 2, 45-53	0.8	1
59	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
58	Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. <i>Liver International</i> , <b>2021</b> , 41, 788-798.9	7.9	5
57	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 340-349	13.4	11
56	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , <b>2021</b> , 10, 126-136	9.1	3
55	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
54	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
53	Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	9
52	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
51	Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. <i>Cancers</i> , <b>2020</b> , 12,	6.6	13
50	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , <b>2020</b> , 29, 189-196	3.8	6

49	Sexual transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A new possible route of infection?. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, e227	4.5	31
48	Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e20874	7.6	9
47	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. <i>Liver Cancer International</i> , <b>2020</b> , 1, 12-24	0.8	1
46	The interpretation of liver function tests in pregnancy. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2020</b> , 44-45, 101667	2.5	1
45	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 292	8.5	26
44	Nicotinamide and NAFLD: Is There Nothing New Under the Sun?. <i>Metabolites</i> , <b>2019</b> , 9,	5.6	8
43	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , <b>2019</b> , 39, 1478-1489	7.9	27
42	Hepatic gene expression in mouse models of non-alcoholic fatty liver disease after acute exercise. <i>Hepatology Research</i> , <b>2019</b> , 49, 637-652	5.1	5
41	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3013-3019	4	20
40	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
39	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , <b>2019</b> , 11,	6.6	25
38	, and Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	1
37	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , <b>2018</b> , 22, 859-871	3.3	17
36	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1123-1130	4	11
35	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , <b>2018</b> , 68, 1232-1244	11.2	15
34	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , <b>2018</b> , 38, 2028-2039	7.9	5
33	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1105-1114	3.3	26
32	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. <i>Oncotarget</i> , <b>2018</b> , 9, 17483-17490	3.3	5

31	Effects of obesity on asthma: immunometabolic links. <i>Polish Archives of Internal Medicine</i> , <b>2018</b> , 128, 469-477	1.9	26
30	Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 2582-2595	5.6	35
29	Anti-tumoral effects of exercise on hepatocellular carcinoma growth. <i>Hepatology Communications</i> , <b>2018</b> , 2, 607-620	6	19
28	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2417-2429	40	176
27	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 65-71	13.4	63
26	Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1193-1200	6.1	18
25	Prevalence of and risk factors for HBV infection in a metropolitan Southern Italian area: Evidence for the effectiveness of universal Hepatitis B vaccination. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1257-1261	3.3	6
24	Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2017</b> , 77, 448-453	2	8
23	Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation-AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 77	6.1	
22	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 198-206	3.1	9
21	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 198-206	3.1	12
20	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	9
19	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 160-168	6.1	58
18	Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2017</b> , 12, 61-67	5	15
17	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 423-433	7.9	34
16	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , <b>2017</b> , 37, 259-270	7.9	50
15	Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 291-297	19.7	31
14	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 860-8	3.3	14

13	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 120-37	3.3	23
12	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 70-7	0.7	42
11	Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2016</b> , 25, 151-7	1.4	40
10	Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 385-99	6.1	33
9	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 814-24	6.1	16
8	Osteoporosis across chronic liver disease. <i>Osteoporosis International</i> , <b>2016</b> , 27, 1967-77	5.3	20
7	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. <i>Journal of Medical Virology</i> , <b>2015</b> , 87, 1368-76	19.7	2
6	Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 214	3	20
5	Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3516-24	5.6	23
4	Vitamin D levels and chronic hepatitis C. <i>E-SPEN Journal</i> , <b>2013</b> , 8, e169-e174		2
3	Garlic extract attenuating rat liver fibrosis by inhibiting TGF- $\beta$ . <i>Clinical Nutrition</i> , <b>2013</b> , 32, 252-8	5.9	24
2	Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 200-8	3.4	23
1	Sustained virological response: a milestone in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 2793-8	5.6	55